Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rhythm and Genpharm to commercialise IMCIVREE in GCC countries
Rhythm Pharmaceuticals and Genpharm Services FZ have announced a partnership to commercialise IMCIVREE (setmelanotide) for patients in Gulf Cooperation Council (GCC) countries.
Metabolic Disorders
-
23 May 2023
-
17 Jun 2022
Rhythm Pharmaceuticals secures FDA approval for sNDA for IMCIVREE to treat BBS
Rhythm Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for IMCIVREE (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome (BBS).